Short answer
Insmed Incorporated (INSM) filed an 8-K current report with the SEC on October 5, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CFO Sara Bonstein departing October 30, 2026.
Insmed Incorporated 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Sara Bonstein departing October 30, 2026
- Successor search underway, creating near-term finance leadership transition risk
- Company states departure unrelated to accounting, financial statements, internal controls or operations disagreements
- Separation benefits governed by Section 6.e of her April 1, 2022 employment agreement
Item 7.01 · Regulation FD Disclosure
- October 5, 2026 press release announces Ms. Bonstein’s separation from Insmed
- Third-quarter 2026 guidance information disclosed, potentially affecting near-term investor expectations
- Exhibit 99.1 contains the detailed guidance and separation announcement
Item EX-99.1 · Exhibit EX-99.1
- CFO Sara Bonstein departs October 30 after nearly seven years, creating a senior finance leadership transition
- No accounting, financial-statement, internal-control, or operational disagreement cited, reducing governance concern
- Full-year 2026 revenue guidance reaffirmed: BRINSUPRI $1.25B-$1.40B and ARIKAYCE $450M-$470M
- Management targets cash-flow positivity next year, supported by more than $4.2B raised during Bonstein’s tenure
- Third-quarter 2026 results scheduled October 29, with Bonstein participating on the earnings call
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Insmed Incorporated 8-K filings
Get the next INSM 8-K as it lands
Follow INSM for push alerts, or ask the research agent what this filing means.